{"prompt": "['10.', 'SAFETY MONITORING DURING THE STUDY', '10.1.', 'Vital Signs', 'Vital signs will be taken at Visits 1 through Visit 6 (Screening through Week 12 post-treatment', 'Visits). This should include temperature, pulse, respiratory rate, and blood pressure when', 'patient is seated. Height and weight are required only at Screening Visit.', '10.2.', 'History/Varicose Vein History/Physical Examination', 'Medical and Vein history will be collected at the Screening (Visit 1). A physical examination', 'will be performed and documented on the appropriate eCRF at Screening Visits.', '10.3.', 'Clinical Laboratory Safety Assessments', 'Hematological Assessments include: hemolysis, hematocrit, reticulocyte count, haptoglobins as', 'described in Section 8.1.', 'Intravascular coagulations include: Plasma fibrinogen level, Plasma D-dimer level platelet', 'count, Prothrombin time (PT), Partial thromboplastin time (PTT) as described in Section 8.1.', 'Plasma D-dimer level assessments will be conducted at: Baseline (Visit 2) immediately post', 'Treatment (Visit 3) and at Week 1 follow-up (V isit 4); then, only at subsequent follow-up visits', '[Week 6 (Visit 5) and Week 12 (Visit 6)] if the D-dimer level is higher than it was at Baseline', 'as described in Section 8.1.', 'Other parameters and/or increased frequency of examinations may be needed, depending on the', 'findings during the clinical study.', '10.4.', 'Post-treatment Local Effects', 'Local effects such as hyperpigmentation, granuloma formation, and ulceration will be', 'monitored.', '10.5.', 'Identification and Description of Thromboembolic Events', 'Identification, description and assessment of venous-thromboembolio events, including as', 'follows:', 'Deep Vein Thrombus (DVT) - Clinical assessment and ultrasound imaging will be', 'performed.', 'Pulmonary Embolism (PE) - Clinical assessment will be performed to evaluate for PE. If', 'clinical assessment is suspicious for PE imaging will be obtained to confirm.', 'Post Ablation Superficial Thrombus Extension (PASTE) - Clinical assessment and', 'ultrasound imaging will be performed.', '10.6.', 'Assessment of Adverse Events', 'Any observed or reported Adverse Event (AE) regardless of treatment group or suspected causal', 'relationship to the ClariVein RES investigational product will be reported as described in', 'Section 10.7.', 'Page 38 of 101']['For all AEs, the Investigator must pursue and obtain information adequate to determine the', 'outcome of the AE; and to assess whether it meets the criteria for classification as a Serious AE', '(SAE). requiring immediate notification to Sponsor or its designated representative.', '10.7.', 'Adverse Event Definition', '10.7.1.', 'Pharmaceutical Product', 'An adverse event (AE) is any untoward medical occurrence in a patient or clinical', 'investigation subject administered a pharmaceutical product. The occurrence, which may or', 'may not have a causal relationship with the investigational treatment, may include any clinical', 'or laboratory change that does not commonly occur in that patient and is considered clinically', 'significant.', 'A suspected adverse reaction means any AE for which there is a \"reasonable possibility\" that', 'the drug caused the AE. For reporting under this protocol, \"reasonable possibility\" means there', 'is evidence to suggest a causal relationship between the drug and the AE.', 'Pre-existing conditions, illnesses present prior to the p signing the Informed Consent Form, are', 'documented on the medical history eCRF. Pre-existing conditions that worsen during the study', 'are entered on the AE eCRF.', 'All out-of-range laboratory values will be deemed as clinically significant or not clinically', 'significant by the Investigator. Clinically significant values will be considered AEs and', 'recorded as such on the eCRFs.', 'Pregnancy is not considered an AE; however, a patient who becomes pregnant after Treatment', 'should be followed as described in Section 10.12.', 'If the patient experiences a worsening or complication of a concurrent condition that was', 'present before exposure to the study drug, the worsening or complication should be recorded as', 'an AE. Investigators should ensure that the AE term recorded captures the change in the', 'condition (e.g., worsening of \" \")', 'Pre-planned procedures (surgeries or therapies) that were scheduled prior to the start of study', 'drug exposure are not considered AEs. However, if a pre-planned procedure is performed', 'earlier than anticipated (e.g., as an emergency) due to a worsening of the pre-existing condition,', 'the worsening of the condition should be captured as an AE.', \"Elective procedures performed where there is no change in the patient's medical condition\", 'should not be recorded as AEs, but should be documented as concomitant procedures.', '10.7.2.', 'Medical Device', 'A Medical Device Report, \"MDR reportable events\" are events that manufacturers become', 'aware of that reasonably suggest that one of their marketed devices may have caused or', 'contributed to a death or serious injury, or has malfunctioned and the malfunction of the device', 'or a similar device that they market would be likely to cause or contribute to a death or serious', 'injury if the malfunction were to recur.', 'Page 39 of 101']\n\n###\n\n", "completion": "END"}